|
|
|
|
||
BMY Investment Analysts' Current Average Forward EPS Estimates Do Not Include Celgene ResultsWhat I am trying to say is that following the acquisition of Celgene (with regulatory approvals), Bristol Myers' forward eps estimates should go up significantly. Don't be fooled by current BMY forward earnings estimates. JMHO. |
return to message board, top of board |